How to Navigate Health Data Privacy Laws in DTP and DTC Pharma Marketing

Pharma marketers have always operated in a highly regulated environment. But as digital privacy enforcement in pharma expands and patient data comes under greater scrutiny, privacy is becoming a much bigger factor in how marketing programs are planned, measured, and optimized.

The DigiPharma Insights/Freshpaint 2026 DTC and DTP Pharma Benchmark Survey uncovered that 100% of pharma marketers say they find privacy constraints are impacting their performance metrics, and six out of 10 say compliance concerns are delaying or changing marketing initiatives. 

For many pharma marketers, the greater level of regulatory scrutiny has easily outpaced the underlying marketing infrastructure. Instead of redesigning how sensitive health data is governed, our research shows that teams are relying on tactical fixes — removing pixels, avoiding ad platforms, or switching to anonymized data — to reduce compliance risk. 

Those workarounds may satisfy today's requirements, but they often come at the expense of campaign performance, attribution, and speed to market.

This blog explores why those tradeoffs are becoming increasingly costly, and how pharma marketers can break the cycle with a privacy-first data foundation that supports compliance and becomes a competitive advantage for growth. 

Key Takeaways:

• Short-term privacy fixes solve today's compliance concerns but create tomorrow's performance problems. Tactics like removing pixels, relying on anonymized data, or avoiding ad platforms may reduce immediate risk, but they also weaken measurement, optimization, and campaign effectiveness over time.
• Emerging health data regulations require a new approach to measurement and campaign optimization. As privacy requirements expand, pharma marketers need ways to activate and measure campaigns that protect sensitive health data without sacrificing the signals that drive performance.
• A safe-by-default data layer enables pharma marketers to maintain compliance while restoring the data needed to drive business growth. By automatically preventing sensitive health data from reaching third-party tools while preserving compliant conversion signals, marketers can achieve stronger performance without increasing privacy risk.

Compliance Workarounds Treat the Symptoms, Not the Cause

Many pharma marketers’ first step for protecting compliance is to stop doing the action that increases risk. Makes sense, right? 

In practice, that often looks like one or more of the following tactics:

• Our research found that 67% of surveyed pharma marketers are protecting compliance by avoiding using certain ad platforms altogether. By removing pixels from platforms like Meta and Google, teams prevent sensitive health data from being shared with these systems.
• 63% are removing third-party tagging and building their own internal or server-side tagging solutions. With complete control over how data is managed, they can ensure sensitive data is collected, stored, and shared without violating data regulations. 
• 54% are shifting from using identifiable patient data to using anonymized data exclusively. If data can’t be tied to an individual patient, it reduces the risk of exposing sensitive health information. 
• And finally 50% of surveyed pharma organizations are manually scrubbing patient data in their systems to ensure that it doesn’t contain any sensitive information. Though this work can be too much for marketing alone; 26% of organizations require heavy IT involvement to keep data clean.

Patchwork and manual compliance solutions treat the symptom — risk exposure — rather than the cause: patient data infrastructure that was never built to safeguard sensitive health data. As a result, pharma organizations end up delaying risk, rather than removing it, which over time erodes performance.

Short-Term Compliance Workarounds Have a Long-Term Marketing Cost

The workarounds described above may appease the privacy team today, but their long-term costs to marketing are steep:

• The 67% of pharma marketing teams that reduce risk by avoiding certain ad platforms altogether surrender reach, targeting precision, and optimization signals on the channels their patients use every day. 
• The 63% that opt to build server-side tagging internally find themselves with a technical burden that creates ongoing IT dependencies, while still failing to solve the underlying patient data governance problem. 
• And the 54% of teams that shift to anonymized data lose the context needed for effective personalization, lookalikes, and retargeting. 

Over time, these compliance fixes create a compounding tax that makes it increasingly difficult for pharma marketers to create engaging experiences, measure performance, and bring campaigns to market. 

As one survey respondent put it, "The constant back and forth drains the team's momentum and slows innovation, leading to more conservative and less effective campaigns."

Marketers and privacy leaders are not enemies

When new compliance requirements are turning your marketing strategy upside down, it’s easy to view privacy as the enemy. If only privacy said “yes” more often, you’d be able to get campaigns to market as quickly as you used to. 

But while marketing and privacy may be in opposition on the surface, our research found that they’re actually looking for the same solution. 

• Pharma Marketers: When asked what a perfect patient data privacy solution would offer, 71% of pharma marketers want privacy-safe analytics and ad activation and 70% want automatic consent enforcement. 
• Pharma Privacy Leaders: When asked what would make a marketing analytics solution trustworthy and privacy-compliant for use in direct-to-patient programs, privacy leaders seek auditability, role-based access, and governance. As one leader described, the solution should provide “built-in guardrails that prevent activation of sensitive health data."

‍
The gap clearly isn’t the goals; both marketing and privacy teams, after all, are looking for a reliable foundation that enables data-driven marketing without compromising on control, visibility, and compliance. 

Instead, the gap is the infrastructure.

And with the cost of inaction rising, partnership between marketing and privacy isn’t a nice-to-have, but a necessity. Just take the recent lawsuit faced by a top 25 pharma company, in which the multinational pharma organization was sued for allegedly sharing patient data from its breast cancer drug websites with third-party tracking platforms. 

How to Tell a Compliance Workaround from a Sustainable Solution: A 5-Step Diagnostic

If the recent rise in privacy enforcement has taught us anything, it’s that privacy restrictions on pharma marketing aren’t going anywhere soon. Rather, they’re likely to expand. 

To navigate privacy laws without sacrificing marketing performance, pharma marketers need to invest in developing compliance solutions for the long term. 

“Mitigating risk while enabling marketing can be an intimidating task, but there are relatively simple measures that, when implemented, can materially lower the risk profile in advertising,” says Mason Fitch, special counsel at law firm Kelley Drye & Warren LLP. “Compliance starts with understanding what tracking technology is on your website and what personal information is being disclosed to whom. From there, it’s an exercise of reducing the amount and quality of information disclosed.”

Use this five-step diagnostic to identify whether your privacy practices hinder or strengthen your DTP and DTC strategies.

1. Audit your current workarounds: Identify every tactic you’re using to reduce privacy risk today.
2. Map sensitive health data flows: Identify every touchpoint (websites, co-pay eligibility flows, patient support portals, etc.) where sensitive health data is being captured into your systems, before it reaches analytics and ad tools.
3. Review your data agreements: Check whether your data processing agreements (DPAs) reflect how your data is actually being collected and shared with third-party systems. Nearly two-thirds of privacy leaders lack full visibility into how data is being managed. 
4. Align marketing and privacy: Get both teams on the same page for goals, guardrails, and infrastructure requirements. 
5. Replace workarounds with a safe-by-default data layer: Move from short-term workarounds to a long-term solution that can remove sensitive health data before it’s shared with third-party tools, enabling compliant conversion signaling and restoring the data context that teams gave up. 

Privacy is the Next Competitive Advantage in Pharma Marketing

The pharma organizations pulling ahead aren’t settling on temporary compliance solutions. They’re investing in a patient data foundation that enables high-performance marketing while also solving compliance requirements. 

Freshpaint is the platform purpose-built to solve privacy and performance for pharma and life sciences companies. With safe-by-default architecture that strips sensitive health data before it reaches third-party tools, Freshpaint enables leading pharma organizations to safely leverage their favorite channels and restore full-funnel attribution through telehealth and online pharmacy handoffs. 

Ready to see what a compliant, high-performance marketing foundation looks like for your organization? Schedule a demo with our team.